SCHEMBL7790927

SCHEMBL7790927

CCOC(=O)C(=O)N(C)Cc1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.59
NPC1 O15118 3/20 0.59
CA12 O43570 1/20 0.54
CA9 Q16790 1/20 0.54
KMT2A Q03164 5/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
RIPK1 Q13546 1/20 0.51
ALDH1A1 P00352 3/20 0.51
L3MBTL1 Q9Y468 2/20 0.51
POLB P06746 2/20 0.51
LMNA P02545 1/20 0.51
HSD17B10 Q99714 1/20 0.51
HTT P42858 1/20 0.51
TSPO P30536 1/20 0.50
MAPK1 P28482 1/20 0.49
MEN1 O00255 3/20 0.49
CHRNB2 P17787 1/20 0.48
CHRNB4 P30926 1/20 0.48
CHRNA3 P32297 1/20 0.48
CHRNA4 P43681 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7185571 0.84 RAB9A (0.56) RAB9ANPC1CA12CA9KMT2A
SCHEMBL9506390 0.83 RAB9A (0.62) RAB9ANPC1CA12CA9KMT2A
SCHEMBL25377037 0.79 SLC6A2 (0.50) KMT2AALDH1A1LMNAMEN1HPGD
SCHEMBL11190772 0.79 RAB9A (0.72) RAB9ANPC1CA12CA9KMT2A
SCHEMBL7415243 0.78 RAB9A (0.53) RAB9ANPC1CA12CA9KMT2A
SCHEMBL1853180 0.77 LPAR1 (0.53) SMN1; SMN2ALDH1A1
SCHEMBL25374119 0.77 TSPO (0.51) KMT2AALDH1A1L3MBTL1POLBLMNA
SCHEMBL1855682 0.77 ALDH1A1 (0.48) NPC1KMT2ASMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL3163935 0.77 NPC1 (0.75) RAB9ANPC1CA12CA9KMT2A
SCHEMBL10861409 0.76 KMT2A (0.55) RAB9ANPC1CA12CA9KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025096637-A1 SUBSTITUTED ARYL SULFONAMIDES FOR USE AS SODIUM CHANNEL INHIBITORS XENON PHARMACEUTICALS INC. (CA) 2025-05-08 WO disclosed
US-20230365749-A1 NOVEL ANTIFOAMING AGENTS UNIVERSITE CLAUDE BERNARD LYON 1 (FR) 2023-11-16 US disclosed
EP-4225828-A1 NOVEL ANTIFOAMING AGENTS PMC Ouvrie (FR) 2023-08-16 EP disclosed
CN-116323754-A Novel defoaming agent PMC OUVRIE 公司 2023-06-23 CN disclosed
WO-2022073921-A1 NOVEL ANTIFOAMING AGENTS PMC OUVRIE (FR) 2022-04-14 WO disclosed
EP-0722715-B1 Cosmetic compositions containing lactate dehydrogenase inhibitors UNILEVER PLC (GB) 2001-10-24 EP disclosed
US-5853742-A Cosmetic compositions containing lactate dehydrogenase inhibitors CHESEBROUGH-POND'S USA CO., DIVISION OF CONOPCO (US) 1998-12-29 US disclosed
US-5690944-A APPLYING TOPICALLY TO SKIN TO PREVENT WRINKLED AND AGED APPEARANCE CHESEBROUGH-POND'S USA CO., DIVISION OF CONOPCO, INC. (US) 1997-11-25 US disclosed
EP-0722715-A1 Cosmetic compositions containing lactate dehydrogenase inhibitors UNILEVER PLC (GB) 1996-07-24 EP disclosed
US-5336778-A Substituted triazoles as angiotensin II antagonists MERCK & CO., INC. (US) 1994-08-09 US disclosed
EP-0409332-A2 Substituted triazoles as angiotensin II antagonists MERCK & CO. INC. (US) 1991-01-23 EP disclosed